Cited by 2,760Metal complexes synthesis and propertiesDNA Repair MechanismsCancer therapeutics and mechanisms

The DOI matches its Crossref record; 193 of the 196 references it cites were found in a registry or an index.

Molecular mechanisms of cisplatin resistance

Galluzzi, L, Senovilla, L, Vitale, I, Michels, J, Martins, I, Kepp, O, Castedo, M, Kroemer, G·2012·Oncogene

DOI 10.1038/onc.2011.384

Open this paper in CoChat — free account

Abstract

Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis. Despite a consistent rate of initial responses, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure. An intense research has been conducted during the past 30 years and several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have been described. Here, we provide a systematic discussion of these mechanism by classifying them in alterations (1) that involve steps preceding the binding of cisplatin to DNA (pre-target resistance), (2) that directly relate to DNA-cisplatin adducts (on-target resistance), (3) concerning the lethal signaling pathway(s) elicited by cisplatin-mediated DNA damage (post-target resistance) and (4) affecting molecular circuitries that do not present obvious links with cisplatin-elicited signals (off-target resistance). As in some clinical settings cisplatin constitutes the major therapeutic option, the development of chemosensitization strategies constitute a goal with important clinical implications.

Integrity signals

Registry

Crossref · 10.1038/onc.2011.384

Cites

193 of 193 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The resurgence of platinum-based cancer chemotherapy
Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
de Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815
Mitochondrial membrane permeabilization in cell death
Kroemer, G., Galluzzi, L., & Brenner, C. (2007) · Physiological Reviews · doi:10.1152/physrev.00013.2006 · Cited by 3,598
Self-citation
Autophagy and the Integrated Stress Response
Kroemer, G., Mariño, G., & Levine, B. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.023 · Cited by 3,506
Self-citation
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints
Sancar, A., Lindsey-Boltz, L. A., Ünsal-Kaçmaz, K., & Linn, S. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073723 · Cited by 3,317
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Self-citation

Flagged first, then by citations

Show all 196 references

3 of the 196 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T et al. (2001). Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95: 92–95. · DOI

Sorted by citations

Items 601–700 of 1,001

Stepwise copper( i ) binding to metallothionein: a mixed cooperative and non-cooperative mechanism for all 20 copper ions
Scheller, J. S., Irvine, G. W., Wong, D. L., Hartwig, A., & Stillman, M. J. (2017) · Metallomics · doi:10.1039/c7mt00041c · Cited by 51
Horizontal transfer of miR-106a/b from cisplatin resistant hepatocarcinoma cells can alter the sensitivity of cervical cancer cells to cisplatin
Raji, G. R., Sruthi, T. V., Edatt, L., Haritha, K., Shankar, S. S., & Kumar, V. B. S. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.07.005 · Cited by 48
Brown Seaweed Fucoidan in Cancer: Implications in Metastasis and Drug Resistance
Reyes, M. E., Riquelme, I., Salvo, T., Zanella, L., Letelier, P. J., & Brebi, P. (2020) · Marine Drugs · doi:10.3390/md18050232 · Cited by 49
The functional role of long noncoding RNA in resistance to anticancer treatment
Qu, Y., Tan, H., Chan, Y.-T., Jiang, H.-B., Wang, N., & Wang, D. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920927850 · Cited by 47
New insights into long non-coding RNAs in non-small cell lung cancer
Ye, R., Tang, R., Gan, S., Li, R., Cheng, Y., Guo, L., Zeng, C., & Sun, Y. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110775 · Cited by 48
Combination Treatment with All-Trans Retinoic Acid Prevents Cisplatin-Induced Enrichment of CD133+ Tumor-Initiating Cells and Reveals Heterogeneity of Cancer Stem Cell Compartment in Lung Cancer
Moro, M., Bertolini, G., Pastorino, U., Roz, L., & Sozzi, G. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000563 · Cited by 50
Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells
Tyler, A., Johansson, A., Karlsson, T., Gudey, S. K., Brännström, T., Grankvist, K., & Behnam‐Motlagh, P. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.05.012 · Cited by 48
Gallium (III) Complexes in Cancer Chemotherapy
Peng, X., Gao, S. W., & Zhang, J. (2021) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.202100953 · Cited by 48
The effect of caffeine on cisplatin-induced apoptosis of lung cancer cells
Wang, G., Bhoopalan, V., Wang, D., Wang, L., & Xu, X. (2015) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-4-5 · Cited by 47
Melatonin attenuates cisplatin-induced acute kidney injury in rats via induction of anti-aging protein, Klotho
Ko, J., Shin, N., Jung, T.-Y., Shin, I., Moon, C., Kim, S., Lee, I.-C., Kim, S., Yun, W.-K., Kim, H.-C., et al. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.04.049 · Cited by 47
Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer
Domvri, K., Zarogoulidis, P., Ziogas, N. K., Zarogoulidis, P., Petanidis, S., Porpodis, Κ., Kioseoglou, E., & Hohenforst‐Schmidt, W. (2017) · Journal of Cancer · doi:10.7150/jca.21783 · Cited by 47
Rauvolfia tetraphylla (Devil Pepper)-Mediated Green Synthesis of Ag Nanoparticles: Applications to Anticancer, Antioxidant and Antimitotic
Vinay, S. P., Udayabhanu, Nagaraju, G., Chandrappa, C. P., & Chandrasekhar, N. (2019) · Journal of Cluster Science · doi:10.1007/s10876-019-01598-5 · Cited by 48
pH- and photothermal-driven multistage delivery nanoplatform for overcoming cancer drug resistance
Huang, W., Zhao, H., Wan, J., Zhou, Y., Xu, Q., Zhao, Y., Yang, X., & Gan, L. (2019) · Theranostics · doi:10.7150/thno.33958 · Cited by 47
Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells
Lernoux, M., Schnekenburger, M., Losson, H., Vermeulen, K., Hahn, H., Gérard, D., Lee, J., Mazumder, A., Ahamed, M., Christov, C., et al. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00839-z · Cited by 49
Plasma‐activated medium induces apoptosis in chemotherapy‐resistant ovarian cancer cells: High selectivity and synergy with carboplatin
Rasouli, M., Mehdian, H., Hajisharifi, K., Amini, E., Ostrikov, K., & Robert, É. (2021) · Plasma Processes and Polymers · doi:10.1002/ppap.202100074 · Cited by 47
SIRT1/PGC-1α/PPAR-γ Correlate With Hypoxia-Induced Chemoresistance in Non-Small Cell Lung Cancer
Xu, R., Luo, X., Ye, X., Li, H., Liu, H., Du, Q., & Zhai, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682762 · Cited by 44
Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia
Šimoničová, K., Janotka, Ľ., Kavcová, H., Sulová, Z., Breier, A., & Messingerová, L. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100805 · Cited by 47
Tip60: updates
Ghobashi, A. H., & Kamel, M. A. E.-N. (2018) · Journal of Applied Genetics · doi:10.1007/s13353-018-0432-y · Cited by 47
Exploiting the potential of autophagy in cisplatin therapy: A new strategy to overcome resistance
García‐Cano, J., Ambroise, G., Pascual‐Serra, R., Carrión, M. C., Serrano‐Oviedo, L., Ortega‐Muelas, M., Cimas, F. J., Sabater, S., Ruiz‐Hidalgo, M. J., Sánchez‐Pérez, I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3902 · Cited by 46
Targeting HDAC/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer
Sun, Y., Bao, X., Ren, Y., Jia, L., Zou, S., Han, J., Zhao, M., Han, M., Li, H., Hua, Q., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1597-y · Cited by 46
Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers
Shi, F., Huang, X., Hong, Z., Lü, N., Huang, X., Liu, L., Liang, T., & Bai, X. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216167 · Cited by 46
The Role of the Dysfunctional Akt-Related Pathway in Cancer: Establishment and Maintenance of a Malignant Cell Phenotype, Resistance to Therapy, and Future Strategies for Drug Development
Romano, G. (2013) · Scientifica · doi:10.1155/2013/317186 · Cited by 46
Synergistic Induction of Apoptosis by Methylseleninic Acid and Cisplatin, The Role of ROS-ERK/AKT-p53 Pathway
Zhang, Y., Zheng, S., Zheng, J.-S., Wong, K., Huang, Z., Ngai, S. M., Zheng, W., Wong, Y.-S., & Chen, T. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400749f · Cited by 46
Dextran-Catechin: An anticancer chemically-modified natural compound targeting copper that attenuates neuroblastoma growth
Vittorio, O., Brandl, M., Cirillo, G., Kimpton, K., Hinde, E., Gaus, K., Yee, E. M. H., Kumar, N., Duong, H. T. T., Fleming, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10201 · Cited by 46
ACE2 overexpression inhibits acquired platinum resistance-induced tumor angiogenesis in NSCLC
Cheng, Q., Zhou, L., Zhou, J., Wan, H., Li, Q. Y., & Feng, Y. (2016) · Oncology Reports · doi:10.3892/or.2016.4967 · Cited by 46
Novel ruthenium(II) triazine complex [Ru(bdpta)(tpy)]2+ co-targeting drug resistant GRP78 and subcellular organelles in cancer stem cells
Purushothaman, B., Arumugam, P., Ju, H., Kulsi, G., Samson, A. A. S., & Song, J. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.07.048 · Cited by 46
Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells
Schmidtova, S., Kaľavská, K., Gercakova, K., Čierna, Z., Miklikova, S., Smolková, B., Buociková, V., Miskovska, V., Durinikova, E., Buríková, M., et al. (2019) · Cancers · doi:10.3390/cancers11091224 · Cited by 45
Apigenin Enhanced Antitumor Effect of Cisplatin in Lung Cancer via Inhibition of Cancer Stem Cells
Li, Y., Chen, X., He, W., Xia, S., Jiang, X., Li, X., Bai, J., Li, N., Chen, L., & Yang, B. (2020) · Nutrition and Cancer · doi:10.1080/01635581.2020.1802494 · Cited by 47
EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer
Okamura, S., Yoshino, H., Kuroshima, K., Tsuruda, M., Osako, Y., Sakaguchi, T., Yonemori, M., Yamada, Y., Tatarano, S., Nakagawa, M., et al. (2021) · BMC Cancer · doi:10.1186/s12885-020-07717-0 · Cited by 46
Novel strategies to improve tumour therapy by targeting the proteins MCT1, MCT4 and LAT1
Wang, Y., Qin, L., Chen, W., Chen, Q., Sun, J., & Wang, G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113806 · Cited by 45
Cisplatin resistance-related multi-omics differences and the establishment of machine learning models
Sui, Q., Chen, Z., Hu, Z., Huang, Y., Liang, J., Bi, G., Bian, Y., Zhao, M., Zhan, C., Lin, Z., et al. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03372-0 · Cited by 45
Targeting of the intracellular redox balance by metal complexes towards anticancer therapy
Murillo, M. I., Gaiddon, C., & Lagadec, R. L. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.967337 · Cited by 45
CHD4 promotes acquired chemoresistance and tumor progression by activating the MEK/ERK axis
Wu, J., Zhou, Z., Li, J., Liu, H., Zhang, H., Zhang, J., Huang, W., He, Y., Zhu, S., Huo, M., et al. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100913 · Cited by 45
Loss-of-function alleles ofP2RX7andTLR4fail to affect the response to chemotherapy in non-small cell lung cancer
Vacchelli, E., Galluzzi, L., Rousseau, V., Rigoni, A., Tesnière, A., Delahaye, N., Schlemmer, F., Menger, L., Sukkurwala, A. Q., Adjemian, S., et al. (2012) · OncoImmunology · doi:10.4161/onci.18684 · Cited by 53
Self-citation
CCN2 Enhances Resistance to Cisplatin-Mediating Cell Apoptosis in Human Osteosarcoma
Tsai, H., Huang, C., Su, H., & Tang, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090159 · Cited by 45
The Tyrosine Kinase Inhibitor E-3810 Combined with Paclitaxel Inhibits the Growth of Advanced-Stage Triple-Negative Breast Cancer Xenografts
Bello, E., Taraboletti, G., Colella, G., Zucchetti, M., Forestieri, D., Licandro, S. A., Berndt, A., Richter, P., D’Incalci, M., Cavalletti, E., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0275-t · Cited by 45
Nicotine Inhibits Cisplatin-Induced Apoptosis via Regulating α5-nAChR/AKT Signaling in Human Gastric Cancer Cells
Jia, Y., Sun, H., Hongqiao, W., Zhang, H., Zhang, X., Xiao, D., Ma, X., & Wang, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149120 · Cited by 45
Histone Deacetylase Inhibitor SAHA as Potential Targeted Therapy Agent for Larynx Cancer Cells
Grabarska, A., Łuszczki, J. J., Nowosadzka, E., Gumbarewicz, E., Jeleniewicz, W., Dmoszyńska‐Graniczka, M., Kowalczuk, K., Kupisz, K., Polberg, K., & Stepulak, A. (2016) · Journal of Cancer · doi:10.7150/jca.16655 · Cited by 46
Design, Multicomponent Synthesis, and Anticancer Activity of a Focused Histone Deacetylase (HDAC) Inhibitor Library with Peptoid-Based Cap Groups
Krieger, V., Hamacher, A., Gertzen, C. G. W., Senger, J., Zwinderman, M. R. H., Marek, M., Romier, C., Dekker, F. J., Kurz, T., Jung, M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00197 · Cited by 46
Gold(III) bis(thiosemicarbazonate) compounds in breast cancer cells: Cytotoxicity and thioredoxin reductase targeting
Rodríguez‐Fanjul, V., López‐Torres, E., Mendiola, M. A., & Pizarro, A. M. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.009 · Cited by 45
Cisplatin liposome and 6-amino nicotinamide combination to overcome drug resistance in ovarian cancer cells
Catanzaro, D., Nicolosi, S., Cocetta, V., Salvalaio, M., Pagetta, A., Ragazzi, E., Montopoli, M., & Pasut, G. (2018) · Oncotarget · doi:10.18632/oncotarget.24708 · Cited by 45
Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis
Huang, W., Liu, Y., Wang, J., Yuan, X., Jin, H.-W., Zhang, L.-R., Zhang, J., Liu, Z.-M., & Cui, J.-R. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.037 · Cited by 45
“Two hits - one stone”; increased efficacy of cisplatin-based therapies by targeting PCNA’s role in both DNA repair and cellular signaling
Søgaard, C. K., Blindheim, A., Røst, L. M., Petrović, V., Nepal, A., Bachke, S., Liabakk, N., Gederaas, O. A., Viset, T., Arum, C., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25963 · Cited by 45
Epigenetic drugs and their molecular targets in testicular germ cell tumours
Jostes, S., Nettersheim, D., & Schorle, H. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0154-x · Cited by 45
Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer
Indini, A., Nigro, O., Lengyel, C. G., Ghidini, M., Petrillo, A., Lopez, S., Raspagliesi, F., Trapani, D., Khakoo, S. S., & Bogani, G. (2021) · Cancers · doi:10.3390/cancers13071663 · Cited by 46
Chemodynamic therapy agents Cu(II) complexes of quinoline derivatives induced ER stress and mitochondria-mediated apoptosis in SK-OV-3 cells
Shen, W., Jia, C., Mo, A., Liang, H., & Chen, Z. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113636 · Cited by 46
Effective treatment of cisplatin-resistant ovarian tumors with a MoS2-based sonosensitizer and nanoenzyme capable of reversing the resistant-microenvironment and enhancing ferroptosis and apoptosis
Ge, H., Du, J., Zheng, J., Xu, N., Yao, Q., Long, S., Fan, J., & Peng, X. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.137040 · Cited by 45
The developmental origin of cancers defines basic principles of cisplatin resistance
Skowron, M. A., Oing, C., Bremmer, F., Ströbel, P., Murray, M. J., Coleman, N., Amatruda, J. F., Honecker, F. U., Bokemeyer, C., Albers, P., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.037 · Cited by 44
CRISPR/Cas9-based genome-wide screening for deubiquitinase subfamily identifies USP1 regulating MAST1-driven cisplatin-resistance in cancer cells
Tyagi, A., Kaushal, K., Chandrasekaran, A. P., Sarodaya, N., Das, S., Park, C., Hong, S., Kim, K.-S., & Ramakrishna, S. (2022) · Theranostics · doi:10.7150/thno.72826 · Cited by 44
Combination therapy based on dual-target biomimetic nano-delivery system for overcoming cisplatin resistance in hepatocellular carcinoma
Huang, Y., Kou, Q., Su, Y., Lu, L., Li, X., Jiang, H., Gui, R., Huang, R., Nie, X., & Li, J. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01840-3 · Cited by 44
Research Progress of Metal Anticancer Drugs
Bai, Y., Aodeng, G., Ga, L., Hai, W., & Ai, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122750 · Cited by 46
APC selectively mediates response to chemotherapeutic agents in breast cancer
VanKlompenberg, M. K., Bedalov, C. O., Soto, K. F., & Prosperi, J. R. (2015) · BMC Cancer · doi:10.1186/s12885-015-1456-x · Cited by 44
miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance
Samuel, P., Pink, R. C., Brooks, S. A., & Carter, D. R. F. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1121107 · Cited by 44
Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines
Skowron, M. A., Melnikova, M., van Roermund, J. G. H., Romano, A., Albers, P., Thomale, J., Schulz, W. A., Niegisch, G., & Hoffmann, M. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19020590 · Cited by 44
Phase I trial of selenium plus chemotherapy in gynecologic cancers
Song, M., Kumaran, M. N., Gounder, M. K., Gibbon, D. G., Nieves‐Neira, W., Vaidya, A. P., Hellmann, M., Kane, M. P., Buckley, B., Shih, W. J., et al. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.07.001 · Cited by 44
Overexpression of the lncRNA FER1L4 inhibits paclitaxel tolerance of ovarian cancer cells via the regulation of the MAPK signaling pathway
Liu, S., Zou, B., Tian, T., Luo, X., Mao, B., Zhang, X., & Lei, H. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28032 · Cited by 44
miR-205-5p Mediated Downregulation of PTEN Contributes to Cisplatin Resistance in C13K Human Ovarian Cancer Cells
Shi, X., Xiao, L., Mao, X., He, J., Ding, Y., Huang, J., Peng, C., & Xu, Z. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00555 · Cited by 45
Nano-Based Systems and Biomacromolecules as Carriers for Metallodrugs in Anticancer Therapy
Poursharifi, M., Wlodarczyk, M. T., & Mieszawska, A. J. (2018) · Inorganics · doi:10.3390/inorganics7010002 · Cited by 44
Selectivity of Terpyridine Platinum Anticancer Drugs for G-quadruplex DNA
Morel, E., Beauvineau, C., Naud‐Martin, D., Guetta, C., Verga, D., Ghosh, D., Achelle, S., Mahuteau‐Betzer, F., Bombard, S., & Teulade‐Fichou, M. (2019) · Molecules · doi:10.3390/molecules24030404 · Cited by 44
Potential effects of allyl isothiocyanate on inhibiting cellular proliferation and inducing apoptotic pathway in human cisplatin-resistant oral cancer cells
Chang, P., Tsai, F., BAU, D.-T., Hsu, Y., Yang, J., Tu, M., & Chiang, S. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.06.025 · Cited by 44
LncRNA-DANCR Interferes With miR-125b-5p/HK2 Axis to Desensitize Colon Cancer Cells to Cisplatin vis Activating Anaerobic Glycolysis
Shi, H., Li, K., Feng, J., Liu, G., Feng, Y., & Zhang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01034 · Cited by 44
Cellular Responses to Platinum-Based Anticancer Drugs and UVC: Role of p53 and Implications for Cancer Therapy
Murray, D. L., & Mirzayans, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165766 · Cited by 43
miR-194-5p inhibits SLC40A1 expression to induce cisplatin resistance in ovarian cancer
Wu, J., Zhang, L., Wu, S., Yi, X., & Liu, Z. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.152979 · Cited by 42
Novel CK2-Specific Pt(II) Compound Reverses Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments
Wang, Y., Wang, X., Xu, G., & Gou, S. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00079 · Cited by 43
Improved Clearance during Treatment of HPV-Positive Head and Neck Cancer through mTOR Inhibition
Coppock, J. D., Wieking, B. G., Molinolo, A., Gutkind, J. S., Miskimins, W. K., & Lee, J. H. (2013) · Neoplasia · doi:10.1593/neo.13432 · Cited by 43
Identification of Cisplatin-Regulated Metabolic Pathways in Pluripotent Stem Cells
von Stechow, L., Ruiz‐Aracama, A., van de Water, B., Peijnenburg, A., Danen, E. H. J., & Lommen, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076476 · Cited by 44
Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin
Roh, J., Kim, E. H., Park, J. Y., & Kim, J. W. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0171 · Cited by 42
p53 overexpression increases chemosensitivity in multidrug-resistant osteosarcoma cell lines
Ye, S., Shen, J. K., Choy, E., Cao, Y., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2944-z · Cited by 43
Platinum(II) Complex-Nuclear Localization Sequence Peptide Hybrid for Overcoming Platinum Resistance in Cancer Therapy
Wlodarczyk, M. T., Dragulska, S. A., Camacho‐Vanegas, O., Dottino, P., Jarzęcki, A. A., Martignetti, J. A., & Mieszawska, A. J. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.7b00921 · Cited by 43
Intracellular second messengers mediate stress inducible hormesis and Programmed Cell Death: A review
Zhou, D. R., Eid, R., Miller, K. A., Boucher, É. L., Mandato, C. A., & Greenwood, M. T. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.01.016 · Cited by 43
Hsp90B enhances MAST1-mediated cisplatin resistance by protecting MAST1 from proteosomal degradation
Pan, C., Chun, J., Li, D., Boese, A. C., Li, J., Kang, J., Umano, A. D., Jiang, Y., Song, L., Magliocca, K. R., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125963 · Cited by 42
p53 Promotes chemoresponsiveness by regulating hexokinase II gene transcription and metabolic reprogramming in epithelial ovarian cancer
Han, C. Y., Patten, D. A., Lee, S. G., Parks, R. J., Chan, D. W., Harper, M., & Tsang, B. K. (2019) · Molecular Carcinogenesis · doi:10.1002/mc.23106 · Cited by 44
Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer
Lin, X.-M., Li, S., Zhou, C., Li, R.-Z., Wang, H., Luo, W., Huang, Y.-S., Chen, L.-K., Cai, J.-L., Wang, T.-X., et al. (2019) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2019.105610 · Cited by 43
Cisplatin Resistance in Osteosarcoma: In vitro Validation of Candidate DNA Repair-Related Therapeutic Targets and Drugs for Tailored Treatments
Fanelli, M., Tavanti, E., Patrizio, M. P., Vella, S., Fernandez-Ramos, A., Magagnoli, F., Luppi, S., Hattinger, C. M., & Serra, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00331 · Cited by 43
Crosstalk of Exosomal Non-Coding RNAs in The Tumor Microenvironment: Novel Frontiers
Jia, Z., Jia, J., Yao, L., & Li, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.900155 · Cited by 44
A conjugated 2D covalent organic framework as a drug delivery vehicle towards triple negative breast cancer malignancy
Das, S. K., Roy, S., Das, A., Chowdhury, A., Chatterjee, N., & Bhaumik, A. (2022) · Nanoscale Advances · doi:10.1039/d2na00103a · Cited by 43
Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin
Folk, W. P., Kumari, A., Iwasaki, T., Pyndiah, S., Johnson, J. C., Cassimere, E. K., Abdulovic-Cui, A. L., & Sakamuro, D. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005699 · Cited by 42
Potential of natural products in osteosarcoma treatment: Focus on molecular mechanisms
Tobeiha, M., Rajabi, A., Raisi, A., Mohajeri, M., Yazdi, S. M., Davoodvandi, A., Aslanbeigi, F., Vaziri, M., Hamblin, M. R., & Mirzaei, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112257 · Cited by 44
Overcoming Chemotherapy Resistance in Germ Cell Tumors
Országhová, Z., Kaľavská, K., Mego, M., & Chovanec, M. (2022) · Biomedicines · doi:10.3390/biomedicines10050972 · Cited by 42
Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells
Karaca, B., Atmaca, H., Bozkurt, E., Kısım, A., Uzunoğlu, S., Karabulut, B., Sezgin, C., Şanlı, U. A., & Uslu, R. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-2469-z · Cited by 42
Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism
Zhao, J., Ren, K., & Tang, J. (2014) · Tumor Biology · doi:10.1007/s13277-014-2543-3 · Cited by 42
EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer
Bradley, A. T., Zheng, H., Ziebarth, A., Sakati, W. R., Branham-O’Connor, M., Blumer, J., Liu, Y., Kistner‐Griffin, E., Rodriguez‐Aguayo, C., Lopez‐Berestein, G., et al. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt489 · Cited by 42
DNA damage-induced apoptosis suppressor (DDIAS), a novel target of NFATc1, is associated with cisplatin resistance in lung cancer
Im, J., Lee, K.-W., Won, K., Kim, B., Ban, H. S., Yoon, S.-H., Lee, Y.-J., Kim, Y., Song, K., & Won, M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.10.011 · Cited by 42
Asplatin enhances drug efficacy by altering the cellular response
Cheng, Q., Shi, H., Wang, H., Wang, J., & Liu, Y. (2016) · Metallomics · doi:10.1039/c6mt00066e · Cited by 42
Aldehyde dehydrogenase 2*2 knock-in mice show increased reactive oxygen species production in response to cisplatin treatment
Kim, J., Chen, C., Yang, J., & Mochly‐Rosen, D. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0338-8 · Cited by 42
Comparative studies on DNA-binding and in vitro antitumor activity of enantiomeric ruthenium(II) complexes
Hong, W., Huang, F., Huan, T., Xu, X., Han, Q., Wang, G., Xu, H. Y., Duan, S., Duan, Y., Long, X., et al. (2017) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2017.11.024 · Cited by 42
Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance
Zhou, W., Sun, W., Yung, M. M. H., Dai, S., Cai, Y., Chen, C., Meng, Y., Lee, J. B., Braisted, J. C., Xu, Y., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0238-8 · Cited by 41
Dimetallic Ru(II) arene complexes appended on bis-salicylaldimine induce cancer cell death and suppress invasion via p53-dependent signaling
Rahman, F., Bhatti, M. Z., Ali, A., Duong, H., Zhang, Y., Ji, X., Lin, Y., Wang, H., Li, Z., & Zhang, D. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.054 · Cited by 42
Half-sandwich IridiumIII N-heterocyclic carbene antitumor complexes and biological applications
Han, Y., Tian, Z., Zhang, S., Liu, X., Li, J., Li, Y., Liu, Y., Gao, M., & Liu, Z. (2018) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2018.09.009 · Cited by 42
miR-211 facilitates platinum chemosensitivity by blocking the DNA damage response (DDR) in ovarian cancer
Wang, T., Hao, D., Yang, S., Ma, J., Yang, W., Zhu, Y., Weng, M., An, X., Wang, X. J., Li, Y., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1715-x · Cited by 42
Synthesis, characterisation and influence of lipophilicity on cellular accumulation and cytotoxicity of unconventional platinum( iv ) prodrugs as potent anticancer agents
Deo, K. M., Sakoff, J. A., Gilbert, J., Zhang, Y., & Aldrich-Wright, J. R. (2019) · Dalton Transactions · doi:10.1039/c9dt04049h · Cited by 42
Mitochondrial DNA targeting and impairment by a dinuclear Ir–Pt complex that overcomes cisplatin resistance
Zhang, C., Guan, R., Liao, X., Ouyang, C., Liu, J., Ji, L., & Chao, H. (2020) · Inorganic Chemistry Frontiers · doi:10.1039/d0qi00224k · Cited by 42
Lipid, polymeric, inorganic-based drug delivery applications for platinum-based anticancer drugs
Boztepe, T., Castro, G. R., & León, I. E. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120788 · Cited by 41
“Pincer movement”: Reversing cisplatin resistance based on simultaneous glutathione depletion and glutathione S-transferases inhibition by redox-responsive degradable organosilica hybrid nanoparticles
Niu, B., Zhou, Y., Liao, K., Wen, T., Lao, S., Quan, G., Pan, X., & Wu, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.013 · Cited by 42
Decreased Levels of GSH Are Associated with Platinum Resistance in High-Grade Serous Ovarian Cancer
Criscuolo, D., Avolio, R., Parri, M., Romano, S., Chiarugi, P., Matassa, D. S., & Esposito, F. (2022) · Antioxidants · doi:10.3390/antiox11081544 · Cited by 41
Cisplatin in the era of PARP inhibitors and immunotherapy
Duan, M., Leng, S., & Mao, P. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108642 · Cited by 45
Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway
Wang, P., Cui, J., Wen, J., Guo, Y., Zhang, L., & Chen, X. (2016) · Oncology Letters · doi:10.3892/ol.2016.5288 · Cited by 41
Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts
Wei, L., Chintala, S., Ciamporcero, E. S., Ramakrishnan, S., Elbanna, M., Wang, J., Hu, Q., Glenn, S. T., Murakami, M., Liu, L., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13062 · Cited by 41
Inhibiting Importin 4-mediated nuclear import of CEBPD enhances chemosensitivity by repression of PRKDC-driven DNA damage repair in cervical cancer
Zhou, Y., Liu, F., Xu, Q., Yang, B., Li, X., Jiang, S., Hu, L.-P., Zhang, X., Zhu, L., Li, Q., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1384-3 · Cited by 41
Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies
Wang, Y., Xie, Q., Tan, H., Liao, M., Zhu, S., Zheng, L., Huang, H., & Liu, B. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105702 · Cited by 41

Authors: Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G.
Affiliations: Inserm (FR)
Université Paris-Sud (FR)
Corresponding author: Kroemer, G
ORCID: Galluzzi, L
Senovilla, L
Vitale, I
Michels, J
Martins, I
Kepp, O
Castedo, M
Kroemer, G
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2011-09-05
Volume: 31
Issue: 15
Pages: 1869-1883
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/onc.2011.384
OpenAlex: W2141037581
Cited by: 2,760
References: 196
Citations by year: 2026: 154 · 2025: 187 · 2024: 244 · 2023: 220 · 2022: 247 · 2021: 308 · 2020: 252 · 2019: 213 · 2018: 169 · 2017: 167 · 2016: 159 · 2015: 160 · 2014: 145 · 2013: 89 · 2012: 44
FWCI: 7.83
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Funders: European Commission
Ligue Contre le Cancer
Fondation Bettencourt Schueller
Labex Immuno-Oncology
Topics: Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords: cisplatin resistance, chemoresistance, platinum anticancer drugs, DNA damage response, mitochondrial apoptosis, chemosensitization, DNA lesions
MeSH terms: Cisplatin, DNA Damage, DNA Repair, Humans, Signal Transduction, DNA Adducts, Drug Resistance, Neoplasm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Molecular mechanisms of cisplatin resistance

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks